Current management of renal cell carcinoma

Ca-A Cancer Journal for Clinicians

Volumn 46, Issue 5, 1996, Pages 284-302

  Sokoloff, Mitchell H ^a   DeKernion, Jean B ^b   Figlin, Robert A ^b   Belldegrun, Arie ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE; FLOXURIDINE; GAMMA INTERFERON; INTERLEUKIN 2; VINBLASTINE;

ADOPTIVE IMMUNOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HORMONAL THERAPY; HUMAN; KIDNEY CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0029852128     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.46.5.284     Document Type: Review

References (121)

1. Parker S, Tong T, Bolden S, Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27.
2. deKernion JB, Belldegrun A: Renal Tumors, in Walsh PC, Retik AB, Stamey TA, Vaughan ED Jr (eds): Campbell's Urology, ed 6. Philadelphia, WB Saunders Co, 1992, pp 1053-1093.
3. Ritchie AW, deKernion JB: The natural history and clinical features of renal carcinoma. Semin Nephrol 1987;7:131-139.
4. Thompson IM, Peek M: Improvement in survival of patients with renal cell carcinoma: The role of the serendipitously detected tumor. J Urol 1988; 140:487-490.
5. Sufrin G, Chasan S, Golio A, Murphy GP: Paraneoplastic and serologic syndromes of renal adenocarcinoma. Semin Urol 1989;7:158-171.
6. Chisholm GD: Nephrogenic ridge tumors and their syndromes. Ann NY Acad Sci 1974;230:403-423.
7. Utz DC, Warren MM, Grcgg JA, et al: Reversible hepatic dysfunction associated with hypernephroma. Mayo Clin Proc 1970;45:161-169.
8. Boxer RJ, Waisman J, Lieber MM, et al: Non-metastatic hepatic dysfunction associated with renal carcinoma. J Urol 1978;199(3):468-471.
9. Maldazys JD, deKernion JB: Prognostic factors in metastatic renal carcinoma. J Urol 1986;136:376-379.
10. deKernion JB, Berry D: The diagnosis and treatment of renal cell carcinoma. Cancer 1980;45: 1947-1956.
11. Hatcher PA, Anderson EE, Paulson DF, et al: Surgical management and prognosis of renal cell carcinoma invading the vena cava. J Urol 1991; 145:20-24.
12. Murphy GP, Mostofi FK: Histologic assessment and clinical prognosis of renal adenoma. J Urol 1970;103:31-36.
13. Ljungberg B, Joanssen H, Stenling R: Prognostic factors in renal cell carcinoma. Int Urol Nephrol 1988;20:115-121.
14. Grignon DJ, Ayala AG, el-Naggar A, et al: Renal cell carcinoma: A clinicopathologic and DNA flow cytometric analysis of 103 cases. Cancer 1989;64:2133-2140.
15. Uhlman DL, Nguyen PL, Manivel JC, et al: Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst 1994;86:1470-1475.
16. Thoenes W, Storkel S, Rumpelt HJ, et al: Chromophobe cell renal carcinoma and its variants: A report on 32 cases. J Pathol 1988;155:277-287.
17. Holland JM: Proceedings: Cancer of the kidney; Natural history and staging. Cancer 1973;32:1030-1042.
18. Beahrs OH (ed): Manual for Staging of Cancer, ed 3. Philadelphia, JB Lippincott Co, 1988, p 200.
19. DaPonte D, Zungri E, Algaba F, Sole-Balcells F: Angiomyolipome renal isole: Etude de 10 cas. J Urol (Paris) 1983;89:267-271.
20. Yamashita Y, Ueno S, Makita O, et al: Hyperechoic renal tumors: Anechoic rim and intratumoral cysts in US, differentiation of renal cell carcinoma from angiomyolipoma. Radiology 1993;188:179-182.
21. Lieber MM: Renal oncocytoma: Prognosis and treatment. Eur Urol 1990;18(suppl 2):17-21.
22. Klinger ME: Secondary tumors of the genitourinary tract. J Urol 1951;65:144-153.
23. Robson CJ, Churchill BM, Anderson W: The results of radical nephrectomy for renal cell carcinoma. Transactions of the American Association of Genitourinary Surgeons 1968;60:122-129.
24. Patel NP, Lavengood RW: Renal cell carcinoma: Natural history and results of treatment. J Urol 1978;119:722-726.
25. Robson CJ: Radical nephrectomy for renal cell carcinoma. J Urol 1963;89:37-42.
26. Robey EL, Schellhammer PF: The adrenal gland and renal cell carcinoma: Is ipsilateral adrenaleclomy a necessary component of radical nephrectomy? J Urol 1986;135:453-455.
27. Sagalowsky AI, Kadesky KT, Ewalt DM, Kennedy TJ: Factors influencing adrenal metastasis in renal cell carcinoma. J Urol 1994;151:1181-1184.
28. Pizzocaro G, Piva L: Pros and cons of retroperitoneal lymphadenectomy in operable renal cell carcinoma. Eur Urol 1990;18(suppl 2):22-23.
29. deKernion JB: Lymphadenectomy for renal cell carcinoma: Therapeutic implications. Urol Clin North Am 1980;7:697-703.
30. Niederhuber JE: Current Therapy in Oncology. St. Louis, BC Decker, 1993, p. 465.
31. Thrasher JB, Robertson JE, Paulson DF: Expanding indications for conservative renal surgery in renal cell carcinoma. Urology 1994; 43:160-168.
32. Proceedings of the Eleventh Scandinavian Transplantation Meeting. Malmo, January 30-31, 1981. Scand J Urol Nephrol 1981;64:1-245.
33. Moll V, Becht E, Ziegler M: Kidney preserving surgery in renal cell tumors: Indications, techniques and results in 152 patients. J Urol 1991;150:319-323.
34. Smith SJ, Bosniak MA, Megibow AJ, et al: Renal cell carcinoma: Earlier discovery and increased detection. Radiology 1989;170:699-703.
35. Amendola MA, Bree RL, Pollack HM, et al: Small renal cell carcinomas: Resolving a diagnostic dilemma. Radiology 1988;166:637-641.
36. Bell ET: Renal Disease, ed. 2. Philadelphia, Lea and Febiger. 1950, p 435.
37. Tsukamoto T, Kumamoto Y, Takahashi A, et al: Tumor size of renal cell carcinoma: Its clinical implication. Urol Int 1992;48:378-383.
38. Palmer JM: Role of partial nephrectomy in solitary or bilateral renal tumors. JAMA 1983;249:2357-2361.
39. Licht MR, Novick AC, Goormastic M: Nephron sparing surgery in incidental versus suspected renal cell carcinoma. J Urol 1994;152:39-42.
40. Licht MR, Novick AC: Nephron sparing surgery for renal cell carcinoma. J Urol 1993;149:1-7.
41. Herr HW: Partial nephrectomy for renal cell carcinoma with a normal opposite kidney. Cancer 1994;73:160-162.
42. Cheng WS, Farrow GM, Zincke H: The incidence of multicentricity in renal cell carcinoma. J Urol 1991;146:1221-1223.
43. Montie JE: Follow-up after partial or total nephrectomy for renal cell carcinoma. Urol Clin North Am 1994;21:589-592.
44. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, et al: Patterns of failure following surgical resection of renal cell carcinoma: Implications for adjuvant local and systemic therapy. J Clin Oncol 1994;12:206-212.
45. Van der Werf-Messing B: Carcinoma of the kidney. Cancer 1973;32:1056-3061.
46. Cherrie RJ, Goldman DG, Lindner A, deKernion JB: Prognostic implications of vena caval extension of renal cell carcinoma. J Urol 1982; 128:910-912.
47. Clayman RV, Gonzalez R, Fraley EE: Renal cell cancer invading the inferior vena cava: Clinical review and anatomic approach. J Urol 1980;123:157-163.
48. deKernion JB, Ramming KP, Smith RB: The natural history of metastatic renal cell carcinoma: A computer analysis. J Urol 1978;120:148-152.
49. Belldegrun A, Koo AS, Bochner B, et al: Immunotherapy for advanced renal cell cancer: The role of radical nephrectomy. Eur Urol 1990; 18(suppl 2):42-45.
50. Belldegrun A, Abi-Aad AS, Figlin RA, deKernion JB: Renal cell carcinoma: Basic biology and current approaches to therapy. Semin Oncol 1991;18(suppl 7):96-101.
51. O'dea MJ, Zincke H, Utz DC, Bernatz PE: The treatment of renal cell carcinoma with solitary metastasis. J Urol 1978;120:540-542.
52. Walther MM, Alexander RB, Weiss GH, et al: Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology 1993;42:250-257.
53. Bloom HJ: Proceedings: Hormone-induced and spontaneous regression of metaslatic renal cancer. Cancer 1973;32:1066-1071.
54. deKernion JB: Treatment of advanced renal cell carcinoma: Traditional methods and innovative approaches. J Urol 1983;130:2-7.
55. Ferrazzi E, Salvagno L, Fornasiero A, et al: Tamoxifen treatment for advanced renal cell cancer. Tumori 1980;66:601-605.
56. Yagoda A: Chemotherapy of renal cell carcinoma: 1983-1989. Semin Urol 1989;7:199-206.
57. Argiles A, Ootaka T, Hill PA, et al: Regulation of human renal adenocarcinoma cell growth by retinoic acid and its interactions with epidermal growth factor. Kidney Int 1994;45:23-31.
58. deKernion JB, Ramming KP: The therapy of renal adenocarcinoma with immune RNA. Invest Urol 1980;17:378-381.
59. Morales A, Wilson JL, Pater JL, Loeb M: Cytoreductive surgery and systemic bacillus Calmette-Guerin therapy in metastatic renal cancer: A phase II trial. J Urol 1982;127:230-235.
60. McCune CS, Schapira DV, Henshaw EC: Specific immunotherapy of advanced renal carcinoma: Evidence for the polyclonality of metastases. Cancer 1981;47:1984-1987.
61. Morgan DA, Ruscetti FW, Gallo R: Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976;193:1007-1008.
62. deKernion JB, Sarna G, Figlin R, et al: The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J Urol 1983;130:1063-1066.
63. Quesada JR, Swanson DA, Gutterman JU: Phase II study of interferon alpha in metastatic renal cell carcinoma: A progress report. J Clin Oncol 1985;3:1086-1092.
64. Figlin RA, deKernion JB, Mukamel E, et al: Recombinant interferon alpha-2a in metastatic renal-cell carcinoma: Assessment of anti-tumor activity and anti-interferon antibody formation. J Clin Oncol 1988;6:1604-1610.
65. Neidhart JA: Interferon therapy for the treatment of renal cancer. Cancer 1986;57(suppl 8): 1696-1699.
66. Vugrin D, Hood L, Laszlo J: A phase II trial of high-dose human lymphoblastoid alpha Interferon in patients with advanced renal carcinoma. Journal of Biologic Response Modifiers 1986;5:309-312.
67. Muss HB, Costanzi JJ, Leavitt R, et al: Recombinant alfa interferon in renal cell carcinoma: A randomized trial of two routes of administration. J Clin Oncol 1987;5:286-291.
68. Kirkwood JM, Harris JE, Vera R, et al: A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: The American Cancer Society collaborative trial. Cancer Res 1985;45:863-871.
69. Sarna G, Figlin R, deKernion J: Interferon in renal cell carcinoma: The UCLA experience. Cancer 1987;59:610-12.
70. Figlin RA, deKernion JB, Maldazys J, Sarna G: Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: A phase I-II trial. Cancer Treat Rep 1985;69:263-267.
71. Minasian LM, Motzer RJ, Gluck L, et al: Interferon alfa-2a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993;11:1368-1375.
72. Sella A, Logothetis CJ, Fitz K, et al: Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin-C) in metastatic renal cell cancer. J Urol 1992;147:573-577.
73. Atzpodien J, Kirchner H, Lopez Hanninen E, et al: Alpha-interferon. interleukin-2 and 5-fluorouracil as a promising biochemotherapy regimen for the management of advanced renal cell carcinoma. Proceedings of the Annual Meeting of the American Society of Clinical Oncology 1993; 12:A708.
74. Sella A, Zukiwski A, Robinson E, et al: Interleukin-2 with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer. Proceedings of the Annual Meeting of the American Society of Clinical Oncology 1994; 13:A733.
75. Fossa SD, de Garis ST, Heier MS, et al: Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma. Cancer 1986;57:1700-1704.
76. Muss HB, Welander C, Caponera M, et al: Interferon and doxorubicin in renal cell carcinoma. Cancer Treat Rep 1985;69:721-722.
77. Creagan ET, Kovach JS, Long HJ, et al: Phase I study of recombinant leukocyte A human interferon combined with BCNU in selected patients with advanced cancer. J Clin Oncol 1986;4:408-413.
78. Quesada JR, Kurzrock R, Sherwin SA, Gutterman JU: Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. Journal of Biologic Response Modifiers 1987;6:20-27.
79. Ellerhorst JA, Kilbourn RG, Amato RJ, et al: Phase II trial of low dose gamma interferon in metastatic renal cell carcinoma. J Urol 1994;152:841-845.
80. Ernstoff MS, Nair S, Bahnson RR, et al: A phase IA trial of sequential administration of reconibinant DNA-produced interferons: Combination reconibinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 1990; 8:1637-1649.
81. Geboers AD, de Mulder PH, Debruyne FM, et al: Alpha and gamma interferon in the treatment of advanced renal cell carcinoma. Semin Surg Oncol 1988;4:191-194.
82. Smith KA: Interleukin-2: Inception, impact, and implications. Science 1988;240:1169-1176.
83. Rosenberg SA: Karnofsky Memorial Lecture: The immunotherapy and gene therapy of cancer. J Clin Oncol 1992;10:180-199.
84. FDA Biological Response Modifiers Advisory Committee Hearings, Washington. DC, 1992.
85. Rosenberg SA, Yang JC, Topalian SL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994;271:907-913.
86. West WH, Tauer KW, Yannelli JR, et al: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:898-905.
87. Fisher RI, Coltman CA Jr, Doroshow JH, et al: Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1988;108:518-523.
88. Rosenberg SA, Lotze MT, Yang JC, et al: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-484.
89. Bukowski RM, Goodman P, Crawford ED, et al: Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: A Southwest Oncology Group Study. J Natl Cancer Inst 1990;82:143-146.
90. Geertsen PF, Hermann GG, von der Maase H, Steven K: Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: A single center phase II study. J Clin Oncol 1992;10:753-759.
91. Weiss GR, Margolin KA, Aronson FR, et al: A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992;10:275-281.
92. Atkins MB, Sparano J, Fisher RI, et al: Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 1993;11:661-670.
93. Rosenberg SA, Lotze MT, Yang JC, et al: Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989;7:1863-1874.
94. Figlin RA, Belldegrun A, Moldawer N, et al: Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: An active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 1992;10:414-421.
95. Mittelman A, Huberman M, Puecio C, et al: A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma. Cancer 1990;66:664-669.
96. Atzpodien J, Korfer A, Franks CR, et at: Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet 1990;335:1509-1512.
97. Hirsh M, Lipton A, Harvey H, et al: Phase I study of interleukin-2 and interferon-alfa-2a as out- patient therapy for patients with advanced malignancy. J Clin Oncol 1990;8:1657-1663.
98. Kirchner H, Korfer A, Palmer PA, et al: Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: The German outpatient experience. Mol Biother 1990; 2:145-154.
99. Ilson DH, Motzer RJ, Kradin RL, et al: A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. J Clin Oncol 1992;10:1124-1130.
100. Lipton A, Harvey H, Givant E, et al: Interleukin-2 and interferon-alpha-2a outpatient therapy for metastatic renal cell carcinoma. J Immunother 1993;13:122-129.
101. Bergmann L, Fenchel K, Weidmann E, et al: Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer: A phase II study. Cancer 1993;72:1733-1742.
102. Vogelzang NJ, Lipton A, Figlin RA: Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: An outpatient multicenter trial. J Clin Oncol 1993;11:1809-1816.
103. Sawczuk IS: Autolymphocyte therapy in the treatment of metastatic renal cell carcinoma. Urol Clin North Am 1993;20:297-301.
104. Gold JE, Osband ME: Autolymphocyte therapy. II: Dependence of in vivo anti-tumor specificity and long-term immunity against murine melanoma and carcinoma on ex vivo activated donor memory T-cells. Clin Immunol Immunopathol 1994;71:325-332.
105. Osband ME, Lavin PT, Babayan RK, et al: Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet 1990;335:994-998.
106. Grimm EA, Mazumder A, Zhang HZ, et al: Lymphokine-activated killer cell phenomenon. J Exp Med 1993;155:1823-1841.
107. Rosenberg SA, Lotze MT, Yang JC, et al: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993; 85:622-632.
108. Parkinson DR, Fisher RI, Rayner AA, et al: Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: Phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J Clin Oncol 1990;8:1630-1636.
109. Dillman RO, Church C, Oldham RK, et al: Inpatient continuous-infusion interleukin-2 in 788 patients with cancer: The National Biotherapy Study Group experience. Cancer 1993;71:2358-2370.
110. Palmer PA, Vinke J, Evers P, et al: Continuous infusion of recombinant interkleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma. Eur J Cancer 1992;28A(6-7):1038-1044.
111. Foon KA, Walther PJ, Bernstein ZP, et al: Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells. J Immunother 1992;11:184-190.
112. Thompson JA, Shulman KL, Benyunes MC, et al: Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. J Clin Oncol 1992;10:960-968.
113. Sznol M, Clark JW, Smith JW 2nd, et al: Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma. J Natl Cancer Inst 1992; 84:929-937.
114. Belldegrun A, Pierce W, Kaboo R, et al: Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as a therapy for metastatic renal cell carcinoma. J Urol 1993;150:1384-1390.
115. Figlin RA, Belldegrun A, Moldawer N, et al: Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: An active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 1992;10:414-421.
116. Bukowski RM, Sharfman W, Murthy S, et al: Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin-2 in human metastatic renal cell carcinoma. Cancer Res 1991;51:4199-4205.
117. Topalian SL, Solomon D, Avis FP, et al: Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: A pilot study. J Clin Oncol 1988; 6:839-853.
118. Steger GG, Pierce WC, Figlin R, et al: Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes: Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo. Clin Immunol Immunopathol 1994;72:237-247.
119. Belldegrun A, Tso CL, Sakata T, et al: Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): Implications for live cancer vaccines. J Natl Cancer Inst 1993;85:207-216.
120. Dranoff G, Jaffee E, Lazenby A, et al: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-3543.
121. Cancer Vaccines: Structural Basis for Vaccine Development. International symposium. New York, October 3-5, 1994.